# SELLAS Life Sciences Nears Phase 3 Trial Analysis as Shares Rise

- URL: https://stocks.freetheai.org/news/sellas-life-sciences-nears-phase-3-trial-analysis-as-shares-rise-0a4498
- Published: 2026-10-12T11:00:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:SLS](https://stocks.freetheai.org/symbols/NASDAQ-SLS)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) is approaching the final analysis for its Phase 3 REGAL trial testing galinpepimut-S in patients with acute myeloid leukemia following salvage therapy. The study has recorded 78 of the 80 required deaths, leaving two events remaining to trigger database lock and blinded review. Alongside the trial progress, company shares rose 3.46% to $11.65 after premarket momentum and social media chatter linked a reserved conference space to potential business deals.

The upcoming trial readout marks a significant clinical milestone for the company's pipeline. Investors are paying close attention to the progress as galinpepimut-S moves toward its final evaluation stage. In addition, preclinical study results showed that another pipeline candidate, SLS009, displayed therapeutic activity in patient-derived pancreatic cancer models, including tumor samples that were resistant to Daraxonrasib treatment.

Looking ahead, market participants will monitor the occurrence of the final two events required to close data collection for the REGAL trial. Observers will also watch for further development updates on SLS009 in solid tumors and any formal announcements regarding corporate partnerships or strategic transactions at the upcoming hematology conference.

## Key points

- SELLAS Life Sciences is two event reports away from final database lock in its Phase 3 REGAL trial of galinpepimut-S for acute myeloid leukemia.
- Preclinical trial data demonstrated that SLS009 showed activity in patient-derived pancreatic cancer models resistant to Daraxonrasib.
- Shares of SELLAS Life Sciences increased 3.46% to $11.65 following premarket movement and merger speculation related to an ASH conference booth.

## Questions and answers

### What is the status of the Phase 3 REGAL trial for SELLAS Life Sciences?

The REGAL trial evaluating galinpepimut-S in acute myeloid leukemia has reached 78 of 80 required deaths, with two events remaining before database lock and blinded analysis.

### Why did SELLAS Life Sciences stock gain over 3 percent?

SELLAS Life Sciences shares rose 3.46% to $11.65 following premarket trading gains and social media speculation linking a reserved conference booth to merger or partnership talks.

### What were the preclinical results for SLS009 in pancreatic cancer?

Preclinical study data showed that SLS009 demonstrated activity in patient-derived pancreatic cancer models, including tumor samples resistant to Daraxonrasib.